Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novocure Ltd Ord Sh (NQ: NVCR )

12.38 +0.15 (+1.23%)
Streaming Delayed Price Updated: 12:32 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 221,826
Open 12.15
Bid (Size) 12.37 (3)
Ask (Size) 12.39 (4)
Prev. Close 12.23
Today's Range 12.01 - 12.55
52wk Range 10.87 - 83.60
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
From Novocure
Via Business Wire
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
From Novocure
Via Business Wire

Performance

YTD
-14.03%
-14.03%
1 Month
-5.28%
-5.28%
3 Month
-9.57%
-9.57%
6 Month
-4.92%
-4.92%
1 Year
-80.67%
-80.67%

More News

Read More
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Novocure to Report First Quarter 2024 Financial Results
From Novocure
Via Business Wire
Why NovoCure Stock Soared 18.3% This Week
Via The Motley Fool
Why Novocure Stock Is Jumping Today
Via The Motley Fool
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
Via Benzinga
Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Via Benzinga
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Novocure Surges And Flashes A Bullish Sign On Promising Results For Brain Cancer Treatment
Via Investor's Business Daily
NovoCure Ltd. (NASDAQ: NVCR) Leading the Way in Thursday Trading Based on Percentage Gain
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO
From Novocure
Via Business Wire
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
NovoCure (NVCR) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Earnings Scheduled For February 22, 2024
Via Benzinga
AI Drives Tech Rebound, Oil Soars, Bitcoin Tumbles: What's Driving Markets Thursday?
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Cancer Focused Novocure Stock Trading Higher Today?
Via Benzinga
Exposures Product Safety
Fastenal Posts Upbeat Earnings, Joins NovoCure, Taiwan Semiconductor Manufacturing And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Veradigm, Aehr Test Systems, Saratoga Investment And Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.